Following the recognition as one of In Vivo's 2025 Rising Leaders by Citeline’s media outlet In Vivo in April 2025, Dr. Lily Zou, Co-founder and CEO of Degron Therapeutics, recently gave an exclusive interview to Citeline to share insights on the company’s development strategy.

Citeline is a leading global provider of data, analytics, and insights to the life sciences and pharmaceutical industries. It has several well-known life sciences industry analysis publications under its umbrella, including In Vivo, Scrip, and Pink Sheet, which provides industry-leading intelligence and insights on pharmaceutical and biotech drug development, regulatory updates, and market trends. Degron Therapeutics is founded on a unique molecular glue degrader (MGD) library derived from proprietary scaffold chemistry. This growing library comprises over 10,000 structurally differentiated MGD compounds, supported by compound-induced proximity and degradation data. The company has a collaboration and license agreement with Takeda to develop novel MGDs across multiple targets in oncology, neuroscience, and inflammation.

Key Takeaways in the Exclusive Interview

• Since its founding in 2021, Degron Therapeutics has advanced a pipeline of molecular glue degraders that are now reaching development, and it anticipates asset-based transactions in addition to platform collaborations.
• The company is planning a Phase I trial of HuR-targeting DEG6498 for certain solid tumors, for which US IND clearance has also been granted.
• Degron is also rapidly advancing internal candidates against undisclosed targets in immunology and inflammation, each with potential to serve as a pipeline-in-a-product opportunity.

Find more details, please visit https://insights.citeline.com/scrip/r-and-d/degron-eyes-deals-for-novel-molecular-glue-degrader-assets-ICUSJW226FA35NMCCB3K7HMNME/

About Degron Therapeutics
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its proprietary molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening and validation systems to discovery a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of clinical and preclinical programs for oncology, inflammation, neurology, and metabolic diseases. For more information, visit www.degrontx.com.